Equities Analysts Set Expectations for CureVac’s Q1 2023 Earnings (NASDAQ:CVAC)

Posted by Defense World Staff on Apr 28th, 2023

CureVac (NASDAQ:CVAC – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for shares of CureVac in a report issued on Tuesday, April 25th. Jefferies Financial Group analyst E. Yang forecasts that the company will post earnings per share of ($0.29) for the quarter. Jefferies Financial Group has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for CureVac’s current full-year earnings is ($0.84) per share. Jefferies Financial Group also issued estimates for CureVac’s Q2 2023 earnings at ($0.27) EPS, Q3 2023 earnings at ($0.27) EPS and Q4 2023 earnings at ($0.26) EPS.

A number of other research firms have also commented on CVAC. UBS Group raised CureVac from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Thursday, January 19th. They noted that the move was a valuation call. JMP Securities reduced their target price on CureVac from $34.00 to $24.00 in a report on Wednesday.

CureVac Trading Up 0.7 %

CureVac stock opened at $7.32 on Thursday. The stock has a fifty day simple moving average of $7.49 and a two-hundred day simple moving average of $7.97. CureVac has a 12 month low of $5.63 and a 12 month high of $20.06. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.61 and a quick ratio of 3.56.

Institutional Trading of CureVac

Several large investors have recently modified their holdings of the company. Vontobel Holding Ltd. grew its holdings in shares of CureVac by 3.8% in the first quarter. Vontobel Holding Ltd. now owns 19,411 shares of the company’s stock worth $381,000 after acquiring an additional 702 shares during the period. Royal Bank of Canada grew its holdings in shares of CureVac by 13.0% in the third quarter. Royal Bank of Canada now owns 11,119 shares of the company’s stock worth $87,000 after acquiring an additional 1,280 shares during the period. SG Americas Securities LLC grew its holdings in shares of CureVac by 11.0% in the fourth quarter. SG Americas Securities LLC now owns 15,407 shares of the company’s stock worth $93,000 after acquiring an additional 1,526 shares during the period. ETF Managers Group LLC grew its holdings in shares of CureVac by 2.8% in the third quarter. ETF Managers Group LLC now owns 55,320 shares of the company’s stock worth $436,000 after acquiring an additional 1,531 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of CureVac by 0.5% in the third quarter. Marshall Wace LLP now owns 333,819 shares of the company’s stock worth $2,629,000 after acquiring an additional 1,758 shares during the period.

CureVac Company Profile

(Get Rating)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.